Trial reportLasers in medical science2025
Comparative efficacy of low-level diode laser therapy with different wavelengths in burning mouth syndrome: a randomized, single-blind trial.
Trial report in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical Efficacy and Safety of Photobiomodulation Therapy for Orofacial Conditions in Older Adults: A Systematic Review of Randomized Controlled Trials.Dentistry journal · 2026Review
- Photobiomodulation Therapy in the Management of Orofacial Neuropathic Pain-WALT Position Paper 2026.Journal of clinical medicine · 2026Review
- Photobiomodulation in the management of oral lesions: a targeted, evidence-based approach.Brazilian oral research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Burning mouth syndrome (BMS) is a chronic condition with no effective treatment currently available. Low-level laser therapy (LLLT) shows promise for neuropathic pain management, but evidence comparing its efficacy across different wavelengths in BMS patients remains limited. This study aimed to assess the clinical efficacy of LLLT with three distinct wavelengths in BMS patients, and to determine the optimal therapeutic wavelength. This study was a single-blind randomized controlled trial, with blinding applied only to the participants. 201 participants were scheduled for enrollment, divided into three groups with 67 individuals each. Finally, 63 participants with BMS were enrolled from April 2019 to December 2022, with 53 completing the study. Randomization was performed using SPSS software to generate random numbers. Participants were sequentially assigned based on their enrollment order to the 660 nm group (n = 10, 50 mW, 1.5 J/cm
Indexed as
Identifiers
40163198What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.